Taken together, these explorations suggest that targeting PGC-1α combination with antitumor immunity can effectively improve the therapeutic efficacy, success in future clinical trials may benefit cancer patients, especially those who are unresponsive to T cell-based monotherapy. This evidence concerns the gene PPARGC1A and cancer.